Moderna is a Massachusetts-based biotechnology company commercialising messenger RNA (mRNA) medicines. Its platform combines mRNA chemistry, lipid nanoparticle (LNP) delivery, and manufacturing process science. The company has moved from a research-stage mRNA pioneer to a commercial vaccine company with approved COVID-19 vaccines — Spikevax and mNEXSPIKE — and an RSV vaccine, mRESVIA. By Q3 2026 it had five approved products after adding mCOMBRIAX/mCOFLU (flu+COVID combination) in Europe/Canada and mFLUSIVA (seasonal influenza vaccine) in the US/Canada. Beyond vaccines, Moderna is advancing oncology therapeutics — most importantly intismeran autogene (mRNA-4157) with Merck — and rare-disease therapeutics such as mRNA-3927 for propionic acidaemia and mRNA-3705 for methylmalonic acidaemia.
Source: 10-K pp.7–14, pp.19–23; 10-Q pp.12, 33–36.
2. Executive Summary
- FY2025 was a transition year: revenue fell to $1.944B** from **$3.236B in FY2024, down 39.9%, as COVID vaccine demand normalised. Net loss narrowed to $2.822B** from **$3.561B, and diluted EPS improved to -$7.26** from **-$9.28.
Source: 10-K pp.104, 141. - Q3 2026 returned to quarterly profit: revenue $1.313B**, up **29%** YoY; net income **$162M vs -$200M**; diluted EPS **$0.38 vs -$0.51.
Source: 10-Q p.7. - 9M 2026: revenue $1.847B**, up **45.9%**; gross profit **$481M, down 43.4% due mainly to the $890M** Arbutus/Genevant settlement-related royalty charge; operating loss **-$2.073B; net loss -$1.963B**; basic/diluted EPS **-$4.93.
Source: 10-Q pp.7, 28, 39. - Liquidity remains strong: cash, cash equivalents and investments were $8.135B** at 31-Dec-2025 and **$7.976B at 30-Sep-2026. Management believes resources fund operations for at least 12 months.
Source: 10-K p.96; 10-Q p.43. - Audit status is clean: unqualified opinion; no going-concern qualification; internal control over financial reporting effective. The key critical audit matter is measurement of product-sales return provisions, reflecting limited historical returns.
Source: 10-K pp.101–102, 142–143. - Investor pivot: the equity story is no longer “COVID cash machine”; it is “respiratory vaccine franchise + intismeran oncology option + cost discipline + cash runway”. The main risks are demand/price pressure, litigation, pipeline setbacks, and dilution from the $3.0B convertible notes.
Source: 10-K pp.44–76; 10-Q pp.26–27, 45–47.
3. Comparative Financial Statements — FY2025 vs FY2024
3.1 Income Statement, item by item
Source: 10-K p.104; EPS from 10-K p.141. USD million.
| Line item | FY2025 | FY2024 | Change $ | Change % | Comment |
|---|---|---|---|---|---|
| Net product sales | 1,818 | 3,109 | -1,291 | -41.5% | COVID volume decline |
| Other revenue | 126 | 127 | -1 | -0.8% | Grant/collaboration/stand-ready mix |
| Total revenue | 1,944 | 3,236 | -1,292 | -39.9% | |
| Cost of sales | 868 | 1,464 | -596 | -40.7% | Lower write-downs partly offset lower sales |
| Research and development | 3,132 | 4,543 | -1,411 | -31.1% | Portfolio prioritisation |
| Selling, general and administrative | 1,018 | 1,174 | -156 | -13.3% | Cost discipline |
| Total operating expenses | 5,018 | 7,181 | -2,163 | -30.1% | |
| Loss from operations | (3,074) | (3,945) | +871 | +22.1% improvement | Less negative |
| Interest income | 314 | 425 | -111 | -26.1% | Lower balances |
| Other expense, net | (8) | (87) | +79 | +90.8% improvement | Lower equity losses/interest |
| Loss before income taxes | (2,768) | (3,607) | +839 | +23.3% improvement | |
| Provision for/(benefit from) tax | 54 | (46) | +100 | n/m | Valuation allowance/tax mix |
| Net loss | (2,822) | (3,561) | +739 | +20.8% improvement | |
| Basic and diluted EPS | (7.26) | (9.28) | +2.02 | +21.8% improvement |
Calculated gross profit: FY2025 $1,076M**; FY2024 **$1,772M; change -$696M / -39.3%. Gross margin: 55.3% vs 54.8%.
Calculated operating margin: -158.1% vs -121.9%. Net margin: -145.2% vs -110.0%.
3.2 Balance Sheet, item by item
Source: 10-K p.103. USD million.
| Line item | 31-Dec-2025 | 31-Dec-2024 | Change $ | Change % |
|---|---|---|---|---|
| Cash and cash equivalents | 2,595 | 1,927 | +668 | +34.7% |
| Investments, current | 3,204 | 5,098 | -1,894 | -37.2% |
| Accounts receivable, net | 184 | 358 | -174 | -48.6% |
| Inventory | 153 | 117 | +36 | +30.8% |
| Prepaid expenses and other current assets | 408 | 599 | -191 | -31.9% |
| Total current assets | 6,544 | 8,099 | -1,555 | -19.2% |
| Investments, non-current | 2,336 | 2,494 | -158 | -6.3% |
| Property, plant and equipment, net | 2,134 | 2,196 | -62 | -2.8% |
| Right-of-use assets, operating leases | 719 | 759 | -40 | -5.3% |
| Other non-current assets | 605 | 594 | +11 | +1.9% |
| Total assets | 12,338 | 14,142 | -1,804 | -12.8% |
| Accounts payable | 317 | 405 | -88 | -21.7% |
| Accrued liabilities | 1,386 | 1,427 | -41 | -2.9% |
| Deferred revenue, current | 99 | 153 | -54 | -35.3% |
| Other current liabilities | 185 | 221 | -36 | -16.3% |
| Total current liabilities | 1,987 | 2,206 | -219 | -9.9% |
| Deferred revenue, non-current | 153 | 58 | +95 | +163.8% |
| Operating lease liabilities, non-current | 653 | 671 | -18 | -2.7% |
| Financing lease liabilities, non-current | 20 | 39 | -19 | -48.7% |
| Long-term debt | 590 | — | +590 | n/m |
| Other non-current liabilities | 285 | 267 | +18 | +6.7% |
| Total liabilities | 3,688 | 3,241 | +447 | +13.8% |
| Additional paid-in capital | 1,382 | 866 | +516 | +59.6% |
| Accumulated other comprehensive income/(loss) | 45 | (10) | +55 | n/m |
| Retained earnings | 7,223 | 10,045 | -2,822 | -28.1% |
| Total stockholders’ equity | 8,650 | 10,901 | -2,251 | -20.7% |
| Total liabilities and equity | 12,338 | 14,142 | -1,804 | -12.8% |
Key balance-sheet reads: cash and investments fell $1.384B** to **$8.135B; working capital fell $1.336B** to **$4.557B; equity fell $2.251B** to **$8.650B; long-term debt appeared at $590M after the Nov-2025 term loan.
Source: 10-K pp.94–96, 103.
3.3 Cash Flow Statement, item by item
Source: 10-K p.108. USD million.
| Line item | FY2025 | FY2024 | Change $ | Change % |
|---|---|---|---|---|
| Net loss | (2,822) | (3,561) | +739 | +20.8% |
| Stock-based compensation | 483 | 429 | +54 | +12.6% |
| Depreciation and amortisation | 215 | 189 | +26 | +13.8% |
| Amortisation/accretion of investments | (67) | (95) | +28 | +29.5% |
| Loss on equity investments, net | 8 | 52 | -44 | -84.6% |
| Other non-cash items | 77 | 60 | +17 | +28.3% |
| Accounts receivable | 156 | 534 | -378 | -70.8% |
| Prepaid expenses and other assets | 153 | 145 | +8 | +5.5% |
| Inventory | (34) | 83 | -117 | n/m |
| Right-of-use assets, operating leases | 38 | (53) | +91 | n/m |
| Accounts payable | (92) | (69) | -23 | worse |
| Accrued liabilities | (2) | (385) | +383 | +99.5% improvement |
| Deferred revenue | 41 | (439) | +480 | n/m |
| Operating lease liabilities | (21) | 28 | -49 | n/m |
| Other liabilities | (6) | 78 | -84 | n/m |
| Net cash used in operating activities | (1,873) | (3,004) | +1,131 | +37.6% improvement |
| Purchases of marketable securities | (5,768) | (6,529) | +761 | +11.7% |
| Proceeds from maturities | 5,563 | 5,562 | +1 | +0.0% |
| Proceeds from sales | 2,353 | 3,967 | -1,614 | -40.7% |
| Purchases of property, plant and equipment | (192) | (1,051) | +859 | +81.7% |
| Purchase of intangible asset | (10) | — | -10 | n/m |
| Net cash provided by investing activities | 1,946 | 1,949 | -3 | -0.2% |
| Proceeds from credit facility | 600 | — | +600 | n/m |
| Payment of credit facility issuance costs | (22) | — | -22 | n/m |
| Proceeds from issuance of common stock | 35 | 56 | -21 | -37.5% |
| Tax payments on net share settlements | (2) | — | -2 | n/m |
| Changes in financing lease liabilities | (18) | (10) | -8 | -80.0% |
| Net cash provided by financing activities | 593 | 56 | +537 | +959% |
| Net increase/(decrease) in cash | 668 | (999) | +1,667 | n/m |
3A. Market Snapshot and Valuation Metrics
Source: Capital Insight BD Dashboard, 2026-11-06; valuation metrics derived from YFinance/market data feeds.
| Metric | Value | Date/Note |
|---|---|---|
| Current Share Price | $254.19 | Close, 2026-11-06 |
| Period High | $267.50 | 2026-11-06 |
| Period Low | $29.81 | 2026-01-02 |
| Year-to-Date Return | +723.69% | 2026-01-01 → 2026-11-06 |
| Annualized Volatility | 209.33% | Dashboard risk module |
| Market Cap | $101.48B | Based on ~399.2M shares |
| Average Volume | 12,389,214 | 214 trading days |
| P/B Ratio | 11.58x | Market Cap / Book Value |
| P/S Ratio | 45.55x | Market Cap / Revenue (TTM) |
| EV/Revenue | 41.54x | Enterprise Value / Revenue |
| P/E, Forward P/E, PEG, EV/EBITDA | n/a (Loss-making) | Meaningless multiples due to negative earnings |
Dashboard Scores: Valuation Score 0.0 (extreme multiples); Quality Score 0.0 (negative ROE/ROA/gross margin); Growth Score 100.0 (improving EPS trend); Composite Score 33.3. These normalized scores reflect a “high-growth narrative + zero current profitability quality + extreme valuation multiples” profile.
Link to Original Analysis: Section 4 ratio analysis could not compute P/B and P/S for FY2025 from the 10-K alone (missing market price). This section fills that gap using dashboard data. P/S of 45.55x against FY2025 revenue of $1.944B implies a market cap of ~**$88.6B; based on 2026 consensus revenue of ~$2.1B–$2.37B, the forward P/S remains exceptionally high at ~43x–48x**, far above the biotechnology industry P/S median (approximately 6x–11x, depending on the data source). The valuation is not pricing current earnings, but rather the long-term cash flow potential of the intismeran oncology option and the respiratory vaccine franchise.
4. Ratio Analysis — FY2025 with FY2024 and US Industry Benchmark Caveat
Source for all inputs: 10-K pp.103–104, 108, 126, 128, 130, 141. Ratios are calculated by this report.
Industry benchmark caveat: the supplied 10-K/10-Q do not contain US industry averages. To comply with “no guess actual data only”, the “USA industry average” column is marked n/a*. Exact averages should be sourced from S&P Capital IQ, Bloomberg, or Damodaran. Qualitatively, versus typical large-cap US pharma, Moderna shows stronger liquidity, lower leverage, lower gross margin, negative profitability, and weaker activity ratios.
| Ratio group | Ratio | FY2025 | FY2024 | Change / read |
|---|---|---|---|---|
| Liquidity | Current ratio | 3.29x | 3.67x | Still very strong; lower |
| Quick ratio | 3.01x | 3.35x | Cash+ST investments+AR / CL | |
| Cash ratio | 2.92x | 3.18x | Very high cash coverage | |
| Working capital | $4,557M | $5,893M | -$1,336M / -22.7% | |
| Leverage/solvency | Total liabilities / total assets | 29.9% | 22.9% | Leverage rose but low |
| Total debt / equity (incl. finance leases) | 7.3% | 0.6% | Term loan added | |
| Net debt / (net cash) | Net cash $7.50B | Net cash $9.52B | Still net cash | |
| Interest coverage (EBIT/interest) | Negative | Negative | Not meaningful | |
| Profitability | Gross margin | 55.3% | 54.8% | Stable but below branded pharma |
| Operating margin | -158.1% | -121.9% | Loss-making | |
| Net margin | -145.2% | -110.0% | Loss-making | |
| R&D / revenue | 161.1% | 140.4% | Heavy R&D burden | |
| SG&A / revenue | 52.4% | 36.3% | Higher expense ratio on lower revenue | |
| ROA | -22.9% | -25.2% | Negative | |
| ROE | -32.6% | -32.7% | Negative | |
| Efficiency/activity | Asset turnover | 0.158x | 0.229x | Lower |
| Inventory turnover (COGS/ending inventory) | 5.67x | 12.51x | Deteriorated | |
| Days inventory outstanding (DIO) | 64.3 days | 29.2 days | Higher | |
| Receivables turnover (revenue/ending AR) | 10.57x | 9.04x | Improved | |
| Days sales outstanding (DSO) | 34.5 days | 40.4 days | Improved | |
| Payables turnover (COGS/ending AP) | 2.74x | 3.62x | Lower | |
| Days payable outstanding (DPO) | 133.3 days | 101.0 days | Higher | |
| Cash conversion cycle | -34.4 days | -31.4 days | Negative; supplier-funded | |
| Cash flow quality | Operating cash flow / net loss | 0.66x | 0.84x | Less cash burn than net loss |
| Capex / revenue | 9.9% | 32.5% | Sharp capex cut | |
| Market/valuation | P/E, P/B, EV/EBITDA | n/a | n/a | Current market price not in filings |
Interpretation: Moderna’s current ratio of 3.29x and net cash position are unusually strong for a commercial-stage biopharma. However, gross margin of 55% is well below the 70%+ typical of large-cap branded pharma, and net margin/ROE are deeply negative. The DSO jump in 9M 2026 to ~202 days is a flag: receivables rose to $1.367B on Q3 sales timing.
Source: 10-Q pp.6, 7, 41.
4A. Profitability Dashboard and Industry Comparison
Source: Capital Insight BD Dashboard, Health Care sector 60-peer comparison; sector averages from the dashboard’s internal peer pool.
| Metric | MRNA | Sector Average | Delta |
|---|---|---|---|
| P/B | 11.58x | 6.15x | +88.4% |
| P/S | 45.55x | 5.12x | +789.9% |
| ROE | -39.00% | 19.47% | -300.3% |
| ROA | -13.26% | 7.45% | -278.0% |
| ROIC | -36.74% | 19.51% | -288.4% |
| Gross Margin | -66.02% (Dashboard basis) | 48.64% | -235.7% |
| Operating Margin | n/a (Loss) | 20.72% | — |
Basis Note: The dashboard’s gross margin of -66.02% is directionally inconsistent with the 10-K calculated FY2025 gross margin of 55.3%. The dashboard may be using TTM data that includes one-time items, different cost definitions, or a current-quarter expense basis. This report treats the 10-K/10-Q as the primary source of financial fact; dashboard margins are for directional reference only and do not replace audited margin data.
Industry Context (Search Sources): The biotechnology industry P/S median is approximately 6x–11x, and P/B is roughly 2.4x–5.1x, significantly below MRNA’s 45.55x P/S and 11.58x P/B. MRNA’s premium is entirely built on pipeline optionality value, not current fundamentals.
5. 9M 2026 Performance at a Glance — Q3 2026 10-Q
Source: 10-Q p.7 for P&L/EPS; p.6 for balance sheet; p.11 for cash flow; p.32 for EPS note. USD million except per-share.
| Metric | 9M 2026 | 9M 2025 | Change | Change % | Note |
|---|---|---|---|---|---|
| Revenue | 1,847 | 1,266 | +581 | +45.9% | COVID international/stand-ready |
| Gross profit (calculated) | 481 | 850 | -369 | -43.4% | Includes ~$890M Arbutus/Genevant charge |
| Operating profit/(loss) | (2,073) | (2,217) | +144 | +6.5% improvement | Less negative |
| Net income/(loss) | (1,963) | (1,996) | +33 | +1.7% improvement | |
| Basic EPS | (4.93) | (5.15) | +0.22 | +4.3% improvement | |
| Diluted EPS | (4.93) | (5.15) | +0.22 | +4.3% improvement | Anti-dilutive in loss |
| NAVPS (equity/shares) | $16.92 | n/a | n/a | n/a | 6,837/404 |
| Net cash flow per basic share | ($3.52) | ($2.05) | -$1.47 | worse | Net decrease in cash / WA shares |
| Total assets | 13,468 | 12,338* | +1,130 | +9.2% | *vs 31-Dec-2025 |
| Total equity | 6,837 | 8,650* | -1,813 | -21.0% | *vs 31-Dec-2025 |
Adjusted gross margin: excluding the $890M** settlement-related royalty charge, 9M 2026 gross profit would be about **$1.371B, or 74.2% margin.
Source: 10-Q pp.7, 28, 39.
5A. Q3 2026 Shareholding Structure and Insider Data
Source: Capital Insight BD Dashboard, 2026-09-30 ownership disclosures.
| Category | Top 10 Aggregate Shares | % of Total Shares | Note |
|---|---|---|---|
| Institutional | 204,765,372 | 51.32% | FMR 13.00%, BlackRock 7.67%, Vanguard combined ~9.7% |
| Mutual Funds | 76,980,861 | 19.29% | Growth Fund of America 3.76% |
| Insiders | 31,508,387 | 7.90% | CEO Stéphane Bancel 5.57%, Noubar Afeyan 1.72% |
Key Takeaway: Institutions and mutual funds collectively control ~70.6%, while insiders hold 7.90%, with Bancel personally holding 5.57%. High institutional concentration implies that large rebalancing flows will amplify volatility (consistent with the dashboard’s 209% annualized volatility). Meanwhile, Bancel’s deep equity stake aligns his interests with long-term shareholder value; his 10b5-1 plan only involves the disposition of expiring options and does not signal a change in long-term conviction.
Link to Original Analysis: 10-K p.144 already disclosed Bancel’s 10b5-1 plan; the dashboard supplements this with the scale of his holdings, providing mutual corroboration.
6. Opportunities and Threats — Investor Lens for New Shareholders
Opportunities
- mNEXSPIKE US retail traction: launched Q3 2025 and became leading US retail product; lower mRNA dose may support cost/positioning.
Source: 10-K p.7. - International government manufacturing partnerships: UK, Canada, Australia facilities licensed in 2025 with multi-year purchase commitments; supports local supply and pandemic readiness.
Source: 10-K p.23; 10-Q p.38. - New product launches: mFLUSIVA approved by FDA Aug-2026 and launched Sep-2026; mCOMBRIAX/mCOFLU approved in EU/Canada. This expands the respiratory franchise beyond COVID/RSV.
Source: 10-Q pp.15, 33–34. - Intismeran oncology option: positive Phase 3 INTeRpath-001 topline in adjuvant melanoma; detailed data showed reduced recurrence/death vs KEYTRUDA alone. Nine Phase 2/3 trials ongoing.
Source: 10-Q p.33; 10-K pp.19–20. - Rare disease collaboration: Recordati deal for mRNA-3927 with $50M upfront** and up to **$110M development/regulatory milestones plus royalties.
Source: 10-Q p.17. - Cost discipline: R&D fell 31% in FY2025 and 20% in 9M 2026; SG&A fell 13% in FY2025.
Source: 10-K p.93; 10-Q p.39. - Strong liquidity and low leverage: $7.976B** cash/investments and **$3.0B convertible notes due 2032 give runway.
Source: 10-Q pp.6, 26–27, 43.
Threats
- COVID demand normalisation: FY2025 product sales fell 42%; future demand remains uncertain.
Source: 10-K pp.87–88, 92. - Intense competition: Pfizer/BioNTech in COVID; Pfizer/GSK in RSV; large pharma in flu/oncology.
Source: 10-K p.44. - Pricing and reimbursement pressure: MFN pricing, IRA Medicare negotiation, ACIP/CDC recommendations, payer consolidation.
Source: 10-K pp.46–47, 68–69. - Pipeline risk: norovirus Phase 3 interim did not meet early-success criteria; CMV congenital programme discontinued; several programmes paused.
Source: 10-Q p.34; 10-K p.16, 23. - Litigation overhang: Arbutus/Genevant potential additional $1.3B; Pfizer/BioNTech, CureVac, GSK (now settled), other patent suits.
Source: 10-Q pp.28–29, 44–45. - Manufacturing/write-down risk: FY2025 inventory write-downs $291M**; 9M 2026 **$133M.
Source: 10-K p.126; 10-Q p.39. - Cash burn and dilution: 9M 2026 operating cash outflow $2.715B**; **$3.0B convertible notes can dilute up to ~14M–21M shares.
Source: 10-Q pp.11, 26–27. - Regulatory/reputational mRNA risk: safety perceptions, policy restrictions, FDA/EMA scrutiny.
Source: 10-K pp.48–51.
7. Audit Objections / Observations That Could Affect Future Earnings
Audit opinion: unqualified; no going-concern qualification; ICFR effective.
Source: 10-K pp.101–102, 142–143.
Critical Audit Matter — product-sales returns: EY identified measurement of provisions for product returns as the most challenging estimate because it depends on inventory remaining in the distribution channel, projected demand, and limited historical returns. This is not an audit objection, but a sensitivity flag: a change in return assumptions can affect reported revenue and accrued liabilities.
Source: 10-K p.102.
Other accounting observations:
- Product-sales provision accrued liability rose to $600M** at 30-Sep-2026 from **$509M at 31-Dec-2025.
Source: 10-Q p.16. - Inventory write-downs: $291M** FY2025; **$133M 9M 2026.
Source: 10-K p.126; 10-Q p.39. - Deferred tax valuation allowance $3.738B at 31-Dec-2025; tax benefits on losses are limited.
Source: 10-K p.139. - Legal contingencies: no accrual for the possible additional $1.3B Arbutus appeal because loss not probable.
Source: 10-Q p.28.
8. Litigation — Current Position and Probable Impact
Source: 10-Q pp.28–29, 44–45; 10-K pp.80–82.
| Matter | Current position | Probable impact / what-if |
|---|---|---|
| Arbutus/Genevant | Settled 3-Mar-2026; $950M** paid Jul-2026; **$876M cost of sales and $74M** intangible recorded. Appeal on 28 U.S.C. §1498 to Federal Circuit; possible additional **up to $1.3B; no accrual. | If $1.3B** becomes probable, pre-tax charge **$1.3B; EPS impact about -$3.27 using 398M basic shares. No tax benefit assumed due valuation allowance. |
| GSK | Settled 28-Oct-2026; cross-licences in infectious disease; no payments. | Removes GSK litigation overhang. |
| Pfizer/BioNTech | EPO Technical Board revoked EP3590949 in Sep-2026; Belgium/Ireland/Netherlands national actions dismissed; Germany/UK pending; new UPC complaint filed Sep-2026. | Adverse patent outcome could affect royalties/injunction risk; no quantified accrual. |
| CureVac | Complaints in UPC (Hague), Spain, Switzerland over mRNA production/composition patents. | Early stage; defence costs and potential damages uncertain. |
| Securities class action (RSV statements) | Dismissed with prejudice 8-Oct-2026; subject to appeal. Derivative cases stayed. | If appealed and revived, defence costs/reputational risk; no material accrual disclosed. |
| Other patent suits | Northwestern, Bayer, mNG Bio, BioNTech, Promosome-related matters. | Individually uncertain; aggregate legal costs could be material. |
EPS sensitivity: for every $100M** of adverse pre-tax litigation charge, EPS impact is about **-$0.25 (100/398). For $1.3B**, about **-$3.27.
Source: 10-Q pp.28, 32.
9. What-If Analysis — Probable Future Earnings Impact
Base assumptions: 398M basic shares (9M 2026), no tax benefit due valuation allowance, adjusted gross margin ~74.2% excluding Arbutus charge. These are sensitivities, not forecasts.
| Scenario | Pre-tax impact | EPS impact | Read |
|---|---|---|---|
| Arbutus additional $1.3B payment | -$1.3B | -$3.27 | Largest single litigation tail risk |
| 10% lower 9M 2026 revenue | -$184.7M revenue; ~-$137M gross profit | -$0.34 | At adjusted gross margin |
| 10% higher product-return provision | +$60M provision | -$0.15 | Accrued liability $600M |
| 10% additional inventory write-down | +$13.3M | -$0.03 | 9M 2026 write-downs $133M |
| Convertible notes fully diluted | +14M shares initially; max ~21M | ~3.5%–5.2% dilution | EPS impact only when profitable; capped call reduces |
| Norovirus programme delay/stop | R&D savings but lost optionality | Not quantifiable | Strategic negative |
Source: 10-Q pp.7, 16, 26–28, 32, 39.
10. Related Party / Strategic Collaboration Transactions
Important: the attached 10-K Item 13 “Certain Relationships and Related Transactions” is incorporated by reference to the proxy statement and is not included in the PDF. The transactions below are strategic collaboration/funding arrangements disclosed in the financial statements; related-party status cannot be confirmed from the supplied files.
| Counterparty | Transaction breakup | Risk/opportunity | Source |
|---|---|---|---|
| Merck — intismeran | FY2025 expenses net of Merck reimbursements $407M**; FY2024 **$390M; FY2023 $184M**. Capex cost recovery **$24M/$109M/$102M. Costs/profits shared equally. | Opportunity: major oncology option. Risk: dependence, cost sharing, disputes. | 10-K pp.121–122 |
| Blackstone — influenza funding | Up to $750M** funding; FY2025 R&D expense reduction **$340M; FY2024 $267M**; liability **$43M/$58M**. Royalties/low single-digit and up to **$750M sales milestones. | Non-dilutive funding; future royalty burden. | 10-K p.122; 10-Q p.17 |
| Recordati — mRNA-3927 | $50M** upfront received Q2 2026; up to **$110M development/regulatory milestones plus commercial milestones/royalties. | Validates rare disease; execution risk. | 10-Q p.17 |
| Vertex — CF | Collaboration revenue $13M** FY2025, **$23M FY2024, $82M FY2023. | Optionality; early stage. | 10-K p.121 |
| Immatics — oncology | $120M upfront paid in 2023; milestones/royalties. | T-cell engager optionality; high risk. | 10-K p.122 |
11. Investment in Other Company Shares
Moderna holds only small equity investments: $6M** at 31-Dec-2025 vs **$14M at 31-Dec-2024; $2M** at 30-Sep-2026 vs **$6M at 31-Dec-2025. These are not strategic control investments.
Source: 10-K p.125; 10-Q p.20.
12. Other Issues Investors Should Note
- Debt: $600M** term loan at ~**9.23%** as of 30-Sep-2026; **$3.0B 0.00% convertible notes due 2032; capped calls cost $329M**. Covenant requires minimum cash of **$500M (rising to **$750M** if >$1.0B drawn).
Source: 10-Q pp.26–27. - Tax: valuation allowance $3.738B; effective tax rate distorted.
Source: 10-K p.139. - Share repurchase: $1.7B remaining authorisation; no shares repurchased in Q3 2026.
Source: 10-Q p.47. - Stock-based compensation: $483M** FY2025; **$351M 9M 2026; dilution management relevant.
Source: 10-K p.136; 10-Q p.30. - Cybersecurity: no material incident disclosed.
Source: 10-K p.77. - CEO trading plan: Stéphane Bancel adopted a 10b5-1 plan for expiring options; no open-market discretionary signal.
Source: 10-K p.144. - Dividend: none.
Source: 10-K p.84.
Fastenal Company (NASDAQ: FAST) — Analytical Equity Research Report
Read Report →13. Source Reference Summary
- 10-K FY2025: business pp.7–14; pipeline pp.19–23; risk factors pp.44–76; legal pp.80–82; MD&A pp.87–97; audit pp.101–102; financial statements pp.103–108; notes pp.121–122, 125–126, 139, 141; controls pp.142–143.
- 10-Q Q3 2026: balance sheet p.6; income statement p.7; cash flow p.11; revenue p.15; settlement p.28; legal pp.28–29, 44–45; convertible notes pp.26–27; MD&A pp.33–43; EPS p.32.
- External benchmark: S&P Capital IQ, Bloomberg, Damodaran Online (US Pharmaceuticals & Drugs) for exact US industry averages — not reproduced here because not included in the supplied filings.
- Capital Insight BD Dashboard (user-provided): Market snapshot, valuation multiples (P/B, P/S, EV/Revenue), sector comparison, ROE/ROA/ROIC/gross margin dashboard basis, ownership structure, volatility/correlation/win rate, analyst scores. Among these, Forward P/E, PEG, EV/EBITDA and other derived metrics are sourced from YFinance/market data feeds, not directly disclosed in company filings; the dashboard gross margin differs from the 10-K audited basis, as explicitly noted in Section 4A.
- StockAnalysis.com (2026-11-06): 23-analyst consensus, target price ranges, FY2026/FY2027 revenue and EPS forecasts.
- Investing.com (2026-11-06): Q4 consensus revenue/EPS, catalyst analysis, FY2026 EPS consensus.
- Business Insider / Markets Insider (2026-11-06): Company FY2026 guidance raised to 15%–25%, consensus revenue $2.1B.
- TipRanks / TheFly (2026-11-06): RBC ($145), BofA ($260), TD Cowen ($110) target price updates.
- Stockrow / Zacks / Finviz (2026): Biotechnology industry P/S, P/B, P/E median/mean, for industry comparison context.
- Company Q3 2026 earnings release and media coverage (2026-11-06): Revenue $1.313B, net income $162M, EPS $0.38, cash $8B, R&D guidance $2.7B, mFLUSIVA/mCOMBRIAX approval status.
- Data Source Priority: Audited/Reviewed 10-K/10-Q > Company Guidance/Releases > Sell-Side Consensus/Dashboard Derived Metrics > Industry Third-Party Medians. All scenario projections are analytical constructs, not company guidance or investment advice.
14. FY2026 and Next Quarter Scenario Projections
14.1 Forecast Basis and Market Consensus
Data Foundation: 9M 2026 actual revenue $1.847B**; Q3 2026 revenue **$1.313B, EPS $0.38**; company raised FY2026 revenue growth guidance to **15%–25%** (based on FY2025 $1.944B, implying $2.24B–$2.43B); year-end cash guidance $8.1B–$8.3B; R&D expense guidance lowered to ~$2.7B**.
Source: 10-Q pp.7, 33–43; Company Q3 guidance.
Market Consensus (Search Sources, for cross-validation):
- FY2026 Revenue Consensus: ~$2.1B–$2.37B (StockAnalysis $2.37B; Business Insider $2.1B; TwelveData next-quarter $675M, FY $2.10B).
- Q4 2026 Revenue Consensus: ~$672M–$675M; Q4 EPS Consensus: -$1.73** (Investing.com) to **-$1.22 (earlier estimate).
- FY2026 EPS Consensus: ~-$8.32** (StockAnalysis) to **-$8.42 (Investing.com).
- FY2027 Revenue Consensus: ~$2.61B**; FY2027 EPS Consensus: ~**-$4.40 (StockAnalysis).
EPS Basis Caution: The FY2026 EPS consensus (~-$8.32 to -$8.42) is significantly worse than the simple sum of 9M 2026 actual EPS (-$4.93) and Q4 consensus (~-$1.73), which would be ~-$6.66. The discrepancy may stem from the fact that Q1–Q2 already absorbed one-time Arbutus settlement-related charges; some analysts may be incorporating additional full-year adjustment items into their consensus. The scenario table below is anchored to actual 10-Q trends and company guidance, while using market consensus as a “floor reference” for the Base Case.
14.2 Three-Scenario Projection Table
Assumptions: Basic weighted-average shares ~398M–401M (9M 2026 base, before potential convertible dilution); tax effects negligible (valuation allowance limits tax benefits); target prices based on a valuation window from late 2026 to early 2027, reflecting market pricing under different pipeline/commercialization assumptions.
Core Assumptions:
🐻 Bear : COVID decline worse than expected; weak mFLUSIVA ramp; Q4 returns to loss; intismeran data “sell the news”; valuation converges toward Citi ($80)/TD Cowen ($110)
⚖️ Base : Midpoint of company guidance (+21%); Q4 revenue ~$675M; minimal mFLUSIVA contribution; intismeran maintains “hold” narrative; near RBC ($145)/Goldman ($137)/consensus (~$145)
🚀 Bull : International COVID government orders stronger than expected; positive early mFLUSIVA prescription data; intismeran 5-year OS trend reinforces “curative” narrative; BofA ($260)/Piper Sandler ($230) pricing
| Scenario | FY2026 Revenue | Q4 2026 Revenue | FY2026 Net Income | FY2026 EPS | Implied P/S | Target Price Range |
|---|---|---|---|---|---|---|
| 🐻 Bear | $2.15B | $0.55B | -$3.5B to -$3.3B | -$8.8 to -$8.3 | ~38x–41x | $80–$110 |
| ⚖️ Base | $2.35B | $0.67B | -$3.3B to -$3.1B | -$8.3 to -$7.8 | ~40x–43x | $130–$155 |
| 🚀 Bull | $2.55B | $0.75B | -$2.9B to -$2.7B | -$7.3 to -$6.8 | ~42x–45x | $220–$260 |
Target Price Note: The target price ranges are not DCF outputs, but scenario ranges based on the current market pricing structure: Bear corresponds to “valuation converging to fundamentals” pessimistic sell-side anchors (Citi $80, TD Cowen $110); Base corresponds to the “hold consensus” midpoint (RBC $145, Goldman $137, 23-analyst mean ~$145); Bull corresponds to “intismeran oncology option being repriced” optimistic anchors (BofA $260, Piper Sandler $230). **The current share price of $254.19 is already near the upper end of the Bull range, meaning the market is pricing in most of the “Bull scenario” probability; the margin of safety for new shareholders is more significant in the Base/Bear scenarios.**
14.3 External Forecast Source Comparison
| Source | FY2026 Revenue | FY2026 EPS | Target Price / Rating | Date |
|---|---|---|---|---|
| StockAnalysis (23 analysts) | $2.37B | -$8.32 | Mean **$145.42**; Hold; Low $45 / High $260 | 2026-11-06 |
| Investing.com Consensus | ~$2.1B | -$8.42 | Q4 EPS -$1.73 | 2026-11-06 |
| Business Insider/Company Guidance | $2.1B consensus (company guidance $2.24B–$2.43B) | — | — | 2026-11-06 |
| Brookline Capital | — | Q4 -$2.09; FY -$6.46 | — | 2026-09-02 |
| RBC Capital | — | — | $145; Sector Perform | 2026-11-06 |
| BofA | — | — | $260; Neutral | 2026-11-06 |
| TD Cowen | — | — | $110; Hold | 2026-11-06 |
| Citi | — | — | $80; Sell | 2026-10-27 |
| Goldman Sachs | — | — | $137; Neutral | 2026-11-03 |
Key Observation: Target prices range from $45 to $260, a >5x spread, which in itself quantifies the current divergence in MRNA’s investment thesis. The consensus mean of ~$145** is ~**43% below** the current price, yet BofA’s **$260 is nearly at the current price. This enormous target price dispersion under a “Hold” rating indicates the market has yet to form a unified valuation framework — this is both a risk and the source of volatility.
15. Disclaimer
This report is for information and educational purposes only. It is not investment advice, a recommendation, or an offer to buy or sell any security. Financial figures are taken from the attached filings and calculations are derived; they are not audited by CapitalinsightBD. Forward-looking statements and what-if sensitivities are illustrative and may differ materially. Investors should read the full 10-K/10-Q, proxy statement, and current market data before investing. Moderna’s stock is volatile and may not be suitable for all investors.
The scenario projections, target price ranges, and probability judgments in this supplemental report are analytical constructs, based on public information and market pricing structure as of 2026-11-06, and do not constitute guarantees of future performance or investment advice. MRNA’s annualized volatility exceeds 200%, and target price dispersion exceeds 5x; any scenario could quickly become invalid due to a single clinical event, regulatory decision, litigation outcome, or financing transaction. Investors should independently verify data, assess their own risk tolerance, and read the company’s complete SEC filings and latest market disclosures.
Md Kollol Hossain
CEO, CapitalinsightBD
info@capitalinsightbd.com
